Articles related to PRECISION MEDICINE

A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.

Single-nucleus multi-omics sequencing across genetically diverse ASD mouse models revealed convergent molecular and cellular changes in early brain development, despite distinct underlying mutations.

An EEG-guided neuromodulation system received FDA clearance for PTSD treatment based on a randomized controlled trial. The platform uses individualized brain activity data to guide therapy, though detailed efficacy results have not been disclosed.

The LRRK2 inhibitor BIIB122 failed to slow disease progression versus placebo in 648 early-stage idiopathic Parkinson’s patients in the Phase 2b LUMA trial, leading Biogen and Denali to discontinue joint development.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital